Ipamorelin is a growth-hormone secretagogue: it asks the pituitary to release a GH pulse rather than replacing GH directly (unlike HGH). The signal passes through the body's own GH-control system, including the feedback brake that ends the pulse. Within GH peptides it's the modern GHRP-style choice — older GHRP-2/GHRP-6 drive a strong pulse but bring more hunger, flushing, cortisol, ACTH, and prolactin; ipamorelin keeps the pulse while reducing that noise. The caveat: its popular at-home use (100–300 mcg SubQ at bedtime, often with CJC-1295 no-DAC or sermorelin) is a peptide-user translation — the published human efficacy program used short-course IV dosing for postoperative ileus and missed its main endpoint.

What Is Ipamorelin?

A synthetic five-amino-acid peptide (not an amino acid, not GH itself) that activates the ghrelin receptor to trigger GH release. HGH adds GH from outside; ipamorelin asks the pituitary to release its own pulse — shaped by pituitary reserve, sleep timing, food timing, glucose status, and feedback control. It's a pulse peptide, not tonic hormone replacement: place a short signal in the right window, usually before sleep.

How Ipamorelin Works

It activates the ghrelin receptor on pituitary somatotrophs to release a GH pulse; the downstream IGF-1 rise carries effects into tissue repair, protein turnover, and body composition. Its selectivity is the useful part: in preclinical work it released GH without the cortisol, ACTH, prolactin, LH, FSH, or TSH movement seen with older GHRPs. Food timing matters because insulin and GH pulses oppose each other — cleanest timing is ≥2 h after food and ~60–90 min before sleep; daytime pulses also separated from food.

Expected Benefits

Best benefit: better overnight recovery when the rest of the system is aligned (deeper sleep, less soreness, stronger morning recovery). Lean-mass support is plausible but not automatic — resistance training and protein decide whether the GH/IGF-1 signal becomes adaptation; without load it can add water/soft weight. Not a primary visceral-fat drug — tesamorelin has the strongest signal there; ipamorelin fits as a pulse companion.

What the Evidence Shows

Three layers, not to be collapsed: (1) Pharmacology — human IV PK shows dose-proportional exposure, ~2 h terminal half-life, renal clearance. (2) Selectivity — Raun et al. described it as a selective GH secretagogue with far less stress-hormone/prolactin spillover (the "cleaner GHRP" basis). (3) Human efficacy — the published program tested IV ipamorelin for postoperative ileus; in the Phase 2 proof-of-concept study it was well tolerated but the primary endpoint did not reach significance. That failure doesn't answer whether bedtime SubQ helps recovery in peptide users — but the absence of a chronic SubQ body-composition trial means claims should be framed as mechanism-plus-practice, not RCT-proven.

Dosing

Start with the bedtime pulse (most aligned with natural GH rhythm). Usual cycle 8–12 weeks, often 5 on / 2 off — a conservative boundary around the missing chronic SubQ data, not a proven tachyphylaxis rule.

CJC + Ipamorelin and Other Stacks

Strongest logic: one GHRH-side signal plus one ghrelin-receptor signal, meeting at the pituitary for a larger pulse than either alone.

Ipamorelin vs GHRP-2 and GHRP-6

Treat ipamorelin as the modern version of the older injectable GHRP idea. GHRP-2 drives a strong pulse but raises cortisol and prolactin; GHRP-6 is appetite-forward (useful only when appetite stimulation is the goal). Ipamorelin isn't side-effect-free, but it's the better default when the desired signal is a short GH pulse without deliberate hunger drive or extra stress-hormone activation.

Side Effects and Safety

Most side effects come from the injection itself or too much GH/IGF-1 for the user's context. Injection-site irritation (redness, itch, welt, warmth) is often local mast-cell activation, not a bad vial. Water retention is the more important systemic sign — puffy fingers, ankle swelling, numbness, or carpal-tunnel-like tingling suggest the signal is too high; escalating through those signs is wrong. GH-axis activation can worsen insulin sensitivity in vulnerable users. Hard cautions: active malignancy, pregnancy, heart-failure history, recent MI, unstable CVD, uncontrolled diabetes, significant edema, disrupted pituitary anatomy.

Histamine, flushing, and injection-site reactions

Itchy bumps, warmth, and brief flushing are usually a local mast-cell response (MRGPRX2) to peptide chemistry/concentration, not true allergy. Wheal-and-flare: itchy bump at the site (local activation). Systemic flushing: warmth/redness across face/neck/chest (faster exposure or lower threshold). Allergic-type symptoms: hives away from the site, facial swelling, throat tightness, wheezing — stop and evaluate clinically. Technique helps: true SubQ depth, slower injection, lower concentration, site rotation. Standard BAC water is usually fine; NaCl BAC water can help recurring welts.